Resultados da busca por Autor

1

Chronic Lung Disease after Premature Birth por Vivek Subbiah

Publicado em 2008

Obter o texto integral
Carta

Salvar na lista

Na minha lista:
2

The next generation of evidence-based medicine por Vivek Subbiah

Publicado em 2023

Obter o texto integral Obter o texto integral
Revisão

Salvar na lista

Na minha lista:
3

Tissue-agnostic cancer therapies: promise, reality, and the path forward por Vivek Subbiah

Publicado em 2025

Obter o texto integral
Artigo

Salvar na lista

Na minha lista:
4

Challenging Standard-of-Care Paradigms in the Precision Oncology Era por Vivek Subbiah, Razelle Kurzrock

Publicado em 2018

Obter o texto integral Obter o texto integral
Revisão

Salvar na lista

Na minha lista:
5

Managing Cancer Care during the COVID-19 Pandemic and Beyond por Omar Alhalabi, Vivek Subbiah

Publicado em 2020

Obter o texto integral Obter o texto integral
Artigo

Salvar na lista

Na minha lista:
6

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: Genomics Is the Diagnosis por Vivek Subbiah, Razelle Kurzrock

Publicado em 2023

Obter o texto integral
Artigo

Salvar na lista

Na minha lista:
7

Tumor-agnostic drug development in dMMR/MSI-H solid tumors por Deepak Bhamidipati, Vivek Subbiah

Publicado em 2023

Obter o texto integral Obter o texto integral
Revisão

Salvar na lista

Na minha lista:
8

Clinical development and management of adverse events associated with FGFR inhibitors por Vivek Subbiah, Srđan Verstovšek

Publicado em 2023

Obter o texto integral Obter o texto integral
Revisão

Salvar na lista

Na minha lista:
9

Advances in Targeting RET-Dependent Cancers por Vivek Subbiah, Gilbert J. Cote

Publicado em 2020

Obter o texto integral
Revisão

Salvar na lista

Na minha lista:
10

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy por Mohamed A. Gouda, Vivek Subbiah

Publicado em 2023

Obter o texto integral
Revisão

Salvar na lista

Na minha lista:
11

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors por Mohamed A. Gouda, Vivek Subbiah

Publicado em 2023

Obter o texto integral Obter o texto integral
Revisão

Salvar na lista

Na minha lista:
12

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers por Mohamed A. Gouda, Vivek Subbiah

Publicado em 2023

Obter o texto integral Obter o texto integral
Revisão

Salvar na lista

Na minha lista:
13

Clinical Development of BRAF plus MEK Inhibitor Combinations por Vivek Subbiah, Christina S. Baik, John M. Kirkwood

Publicado em 2020

Obter o texto integral Obter o texto integral
Revisão

Salvar na lista

Na minha lista:
14

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm por Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

Publicado em 2020

Obter o texto integral Obter o texto integral
Revisão

Salvar na lista

Na minha lista:
15

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives por Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

Publicado em 2017

Obter o texto integral Obter o texto integral
Artigo

Salvar na lista

Na minha lista:
16

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians por Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

Publicado em 2020

Obter o texto integral
Editorial

Salvar na lista

Na minha lista:
17

State-of-the-Art Strategies for Targeting RET-Dependent Cancers por Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

Publicado em 2020

Obter o texto integral
Revisão

Salvar na lista

Na minha lista:
18

The abscopal effect in patients with cancer receiving immunotherapy por Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

Publicado em 2023

Obter o texto integral Obter o texto integral
Revisão

Salvar na lista

Na minha lista:
19

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? por Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

Publicado em 2025

Obter o texto integral
Revisão

Salvar na lista

Na minha lista:
20

The emerging role of PI3K inhibitors for solid tumour treatment and beyond por Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

Publicado em 2023

Obter o texto integral
Revisão

Salvar na lista

Na minha lista:

Chronic Lung Disease after Premature Birth por Vivek Subbiah

The next generation of evidence-based medicine por Vivek Subbiah

Tissue-agnostic cancer therapies: promise, reality, and the path forward por Vivek Subbiah

Challenging Standard-of-Care Paradigms in the Precision Oncology Era por Vivek Subbiah, Razelle Kurzrock

Managing Cancer Care during the COVID-19 Pandemic and Beyond por Omar Alhalabi, Vivek Subbiah

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: <i>Genomics Is the Diagnosis</i> por Vivek Subbiah, Razelle Kurzrock

Tumor-agnostic drug development in dMMR/MSI-H solid tumors por Deepak Bhamidipati, Vivek Subbiah

Clinical development and management of adverse events associated with FGFR inhibitors por Vivek Subbiah, Srđan Verstovšek

Advances in Targeting RET-Dependent Cancers por Vivek Subbiah, Gilbert J. Cote

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy por Mohamed A. Gouda, Vivek Subbiah

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E–Positive Adult and Pediatric Solid Tumors por Mohamed A. Gouda, Vivek Subbiah

Precision oncology with selective RET inhibitor selpercatinib in <i>RET</i>-rearranged cancers por Mohamed A. Gouda, Vivek Subbiah

Clinical Development of BRAF plus MEK Inhibitor Combinations por Vivek Subbiah, Christina S. Baik, John M. Kirkwood

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm por Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives por Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians por Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers por Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

The abscopal effect in patients with cancer receiving immunotherapy por Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? por Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

The emerging role of PI3K inhibitors for solid tumour treatment and beyond por Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

Resultados da busca - Vivek Subbiah

Chronic Lung Disease after Premature Birth por Vivek Subbiah

The next generation of evidence-based medicine por Vivek Subbiah

Tissue-agnostic cancer therapies: promise, reality, and the path forward por Vivek Subbiah

Challenging Standard-of-Care Paradigms in the Precision Oncology Era por Vivek Subbiah, Razelle Kurzrock

Managing Cancer Care during the COVID-19 Pandemic and Beyond por Omar Alhalabi, Vivek Subbiah

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: <i>Genomics Is the Diagnosis</i> por Vivek Subbiah, Razelle Kurzrock

Tumor-agnostic drug development in dMMR/MSI-H solid tumors por Deepak Bhamidipati, Vivek Subbiah

Clinical development and management of adverse events associated with FGFR inhibitors por Vivek Subbiah, Srđan Verstovšek

Advances in Targeting RET-Dependent Cancers por Vivek Subbiah, Gilbert J. Cote

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy por Mohamed A. Gouda, Vivek Subbiah

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E–Positive Adult and Pediatric Solid Tumors por Mohamed A. Gouda, Vivek Subbiah

Precision oncology with selective RET inhibitor selpercatinib in <i>RET</i>-rearranged cancers por Mohamed A. Gouda, Vivek Subbiah

Clinical Development of BRAF plus MEK Inhibitor Combinations por Vivek Subbiah, Christina S. Baik, John M. Kirkwood

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm por Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives por Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians por Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers por Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

The abscopal effect in patients with cancer receiving immunotherapy por Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? por Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

The emerging role of PI3K inhibitors for solid tumour treatment and beyond por Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

Ferramentas de busca:

Assuntos relacionados